Navigation Links
Michigan Success Lands National Research Contract to Reduce Hospital-Associated Infections in 10 States
Date:10/1/2008

Modeled After Highly Successful MHA Keystone: ICU Patient Safety Program

LANSING, Mich., Oct. 1 /PRNewswire/ -- The Agency for Healthcare Research and Quality (AHRQ) today announced a three-year, $3 million national effort to reduce patients' risk of hospital-associated infections in intensive care units (ICUs).

This first-of-its-kind project is modeled after the pioneering efforts of the Michigan Health & Hospital Association's (MHA) Keystone Center for Patient Safety & Quality and Johns Hopkins University (JHU) Quality and Safety Research Group that have achieved significant and measurable improvements in reducing Central-Line Associated Bloodstream Infections (CLABSI) in Michigan hospital ICUs.

In 2003, the MHA Keystone Center launched its first patient safety improvement program - MHA Keystone: ICU - in more than 100 Michigan hospital ICUs. Through a series of back-to-basic patient safety interventions, this collaborative has since resulted in more than 1,700 lives saved, more than 127,000 excess hospital days avoided and more than $246 million in health care costs saved.

"As a result of the MHA Keystone Center, Michigan hospital ICUs are now among the safest in the nation and world," said MHA President Spencer Johnson. "Through the MHA Keystone Center, Michigan hospitals are implementing groundbreaking and lifesaving interventions that have reduced medical errors and health care costs, while improving the quality of patient care delivered at the bedside. Michigan hospitals are truly leading the nation in proactive efforts to make health care safer."

The national project, "National Implementation of the Comprehensive Unit-Based Safety Program (CUSP) to Reduce CLABSI in the ICU", began Sept. 30, 2008, and continues through Sept. 29, 2011. A major goal of the project is to reduce the average rate of CLABSI in participating hospitals to one infection for every 1,000 catheter days. The national average is currently five infect
'/>"/>

SOURCE Michigan Health & Hospital Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Alert Alarm Michigan Seeks Employees With Inside and Outside Sales Experience
2. Deer Farm Industry in Michigan Issues Statement on the Recent Chronic Wasting Disease Case Identified on a Kent County Deer Farm
3. RMA of Michigan Hosts 1st Metro Detroit Area Hope Uncorked: Exclusive Wine Tasting Event To Benefit Fertile Hope
4. Michigan-based Company Introduces Discount Prescription Drug Program
5. Select Michigan and Associated Food & Petroleum Dealers Launch Buy Local, Eat Fresh
6. National Class Action Filed Against Manufacturer of Digitek(R) (Prescription Drug) in Federal Court in Michigan
7. Blue Cross Blue Shield of Michigans Proposed Reforms Make Little Progress With State Senate
8. Blue Cross Blue Shield of Michigan Responds to Attorney Generals Complaint, Says Transaction Was Legal and Fully Authorized
9. SXC Health Solutions announces informedRx renewal contract with The University of Michigan
10. Michigan Health & Hospital Association Elects 2008 Officers and Board Members, Bestows Awards
11. Brain Injury Association of Michigan Outlines the Current State of Brain Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... 16, 2014) The cause of neuronal death in ... proposes that neurons may be mistaken for foreign invaders ... to the way autoimmune diseases like type I diabetes, ... The study was published April 16, 2014, in ... likely controversial, idea in Parkinson,s disease; but if true, ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
(Date:4/17/2014)... (17 April 2014) Population Council scientists and their partners ... stable, and can prevent the transmission of multiple sexually ... in animals: HIV, herpes simplex virus 2 (HSV-2), and ... first data that the gel is effective against multiple ... in the vagina against all three viruses of at ...
(Date:4/17/2014)... D.C. -- The world is less than 40 years ... implications for people and governments, according to a top ... the first time in human history, food production will ... of land, water and energy," said Dr. Fred Davies, ... security. "Food issues could become as politically destabilizing by ...
Breaking Medicine News(10 mins):Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Food shortages could be most critical world issue by mid-century 2
... conducted this study which was self funded. The sweetness ... of the sweetener. // The researchers questioned about 30 ... sweeteners and sweet substances. This was done to detect ... with each substance. Sugar was rated highest. Participants found ...
... with fish oil supplements in teenagers.,Durham County Council’s senior ... 25 teenagers who had been rated with moderate to ... omega-3 fish and omega-6 evening primrose oil over a ... students aged 12 to 15 also had a high ...
... Prime Minister, Shaukat Aziz has been urged by the Poultry ... the poultry industry//. The industry is under crisis over the ... flu scare and the earthquake that hit the country on ... President of the Lahore Chamber of Commerce and Industry (LCCI) ...
... developed at Leeds that will benefit at large in ... the next generation// of miniaturized computers. ,By suspending ... and Dr Yulong Ding have created ‘nanofluids’ which can ... In a central heating system, nanofluids could increase efficiency ...
... Court, would ensure that patients or their relatives would be ... demand. Until now, patients and family members have been facing ... doctor or hospital as they tend to treat it as ... it is their property and therefore refuse to give the ...
... jointly by University of California, Berkeley, and Chilean researchers says ... in drinking water are more likely to succumb to lung ... in their adult life. ,It was found that ... than normal if the child's mother also drank the arsenic-contaminated ...
Cached Medicine News:Health News:Sweet, Sweeter and Sweetest 2Health News:Poultry Industry Of Pakistan Stresses On Need Of Relief Package 2Health News:Arsenic in Drinking Water Predisposes Children To Lung Cancer in Later Life 2
(Date:1/15/2014)... 15, 2014 Tegra Medical is very pleased to announce ... its new Chief Executive Officer.  Mark was promoted from his ... overseen the company,s four facilities in Massachusetts ... King joined Tegra Medical in 2012 with 20+ years of ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... the extracellular matrix for the endocrinology, oncology, dermatology, ... of patient dosing for a Phase 1 clinical ... human hyaluronidase enzyme (rHuPH20) as a subcutaneous (SC) ...
... (Nasdaq: ALXA ) today announced positive results ... loxapine). This Phase 3,clinical trial was conducted in ... 5 mg and 10 mg doses of AZ-004 met ... significant reduction in,agitation from baseline to the 2-hour post-dose ...
Cached Medicine Technology:Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme 2Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme 3Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 2Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 3Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 4Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 5Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 6Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 7Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 8Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 9Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 10
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: